A detailed history of Winton Group LTD transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Winton Group LTD holds 97,235 shares of DVAX stock, worth $1.24 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
97,235
Previous 82,403 18.0%
Holding current value
$1.24 Million
Previous $925,000 17.08%
% of portfolio
0.08%
Previous 0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.05 - $11.61 $149,061 - $172,199
14,832 Added 18.0%
97,235 $1.08 Million
Q2 2024

Aug 09, 2024

BUY
$10.73 - $12.58 $75,378 - $88,374
7,025 Added 9.32%
82,403 $925,000
Q1 2024

May 14, 2024

BUY
$11.7 - $14.98 $486,965 - $623,482
41,621 Added 123.3%
75,378 $935,000
Q4 2023

Feb 12, 2024

SELL
$13.09 - $14.98 $15,708 - $17,976
-1,200 Reduced 3.43%
33,757 $471,000
Q3 2023

Nov 13, 2023

SELL
$12.64 - $14.99 $140,847 - $167,033
-11,143 Reduced 24.17%
34,957 $516,000
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.17 $641,077 - $857,156
-65,084 Reduced 58.54%
46,100 $595,000
Q1 2023

May 12, 2023

BUY
$9.44 - $11.88 $161,877 - $203,718
17,148 Added 18.24%
111,184 $1.09 Million
Q4 2022

Feb 14, 2023

BUY
$10.27 - $13.29 $118,556 - $153,419
11,544 Added 13.99%
94,036 $1 Million
Q3 2022

Nov 10, 2022

BUY
$9.93 - $17.44 $16,444 - $28,880
1,656 Added 2.05%
82,492 $861,000
Q2 2022

Aug 10, 2022

BUY
$7.45 - $12.83 $298,350 - $513,803
40,047 Added 98.18%
80,836 $1.02 Million
Q1 2022

May 11, 2022

BUY
$9.75 - $14.44 $59,426 - $88,011
6,095 Added 17.57%
40,789 $442,000
Q4 2021

Feb 10, 2022

BUY
$13.17 - $20.94 $456,919 - $726,492
34,694 New
34,694 $488,000
Q2 2018

Aug 20, 2018

SELL
$15.15 - $20.75 $151,787 - $207,894
-10,019 Closed
0 $0
Q1 2018

May 21, 2018

BUY
$14.65 - $19.9 $146,778 - $199,378
10,019 New
10,019 $0

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.61B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.